Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina

Abstract

Compositions and methods for treating disorders of the outer retina with β-adrenoceptor antagonists are disclosed.

1 . A method for treating disorders of the outer retina, which comprises administering a pharmaceutically effective amount of a β-adrenoceptor antagonist.  
     
     
         2 . The method of  claim 1  wherein the disorder is selected from the group consisting of ARMD; RP and other forms of heredodegenerative retinal disease; retinal detachment and tears; macular pucker; ischemia affecting the outer retina; damage associated with laser therapy (grid, focal, and panretinal) including photodynamic therapy; thermal or cryotherapy; trauma; surgical (retinal translocation, subretinal surgery, or vitrectomy) or light-induced iatrogenic retinopathy; and preservation of retinal transplants.  
     
     
         3 . The method of  claim 1  wherein the β-adrenoceptor antagonist is selected from the group consisting of: betaxolol (R or S or racemic), timolol, carteolol, levobunolol, metipranolol, befunolol, propranolol, metoprolol, atenolol, pendolol, and pinbutolol.  
     
     
         4 . The method of  claim 3  wherein the β-adrenoceptor antagonist is betaxolol or its R or S isomer.  
     
     
         5 . The method of  claim 2  where the β-adrenoceptor antagonist is selected from the group consisting of: betaxolol (R or S or racemic), timolol, carteolol, levobunolol, metipranolol, befunolol, propranolol, metoprolol, atenolol, pendolol, and penbutolol.  
     
     
         6 . The method of  claim 5  wherein the β-adrenoceptor antagonist is betaxolol or its R or S isomer.